Header Logo

Connection

SHANNON RONCA to Adjuvants, Immunologic

Back to Details
This is a "connection" page, showing publications SHANNON RONCA has written about Adjuvants, Immunologic.
SHANNON RONCA
Connection Strength
0.046
Adjuvants, Immunologic
  1. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452. Vaccine. 2023 03 24; 41(13):2184-2197.
    View in: PubMed
    Score: 0.046
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.